<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6434">
  <stage>Registered</stage>
  <submitdate>19/01/2016</submitdate>
  <approvaldate>19/01/2016</approvaldate>
  <nctid>NCT02725372</nctid>
  <trial_identification>
    <studytitle>Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH</studytitle>
    <scientifictitle>A Phase 3, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Efficacy, Safety, and Tolerability of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Symptomatic Subjects With PAH (Part 1 and Part 2)</scientifictitle>
    <utrn />
    <trialacronym>INOvation-1</trialacronym>
    <secondaryid>PULSE-PAH-004</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pulmonary Arterial Hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Inhaled Nitric Oxide 75 mcg/kg IBW/hr
Treatment: drugs - Placebo

Experimental: Inhaled Nitric Oxide 75mcg/KgIBW/Hr - Part 1:
15Mcg/kg IBW/hr during Run-in Period dose titrated to Inhaled Nitric Oxide / 75mcg/KgIBW/Hr upon randomization to treatment arm.
Part 2: iNO 75 mcg/kg IBW/hr Open Label Treatment

Placebo Comparator: Placebo - Part 1:
Placebo dose setting 15mcg/kg IBW/hr Run In Period / Placebo dose setting 75 mcg/kg IBW/hr treatment period
Part 2: iNO 75 mcg/kg IBW/hr Open Label Treatment


Treatment: drugs: Inhaled Nitric Oxide 75 mcg/kg IBW/hr
Inhaled Nitric Oxide 15mcg/Kg IBW/hr for two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period (Week 3 to Week 18)

Treatment: drugs: Placebo
Placebo arm: Inhaled Nitric Oxide 15mcg/Kg IBW/hr

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Six Minute Walk Distance (6MWD) - Change from baseline 6MWD at 18 Weeks - Change in 6MWD from baseline to 18 weeks</outcome>
      <timepoint>Change from baseline to 18 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Clinical Worsening (TTCW) - 1. TTCW, the time (in days) from start of treatment to first event (first day the event is noted), with iNO as compared to placebo, measured from baseline to 18 weeks . TTCW event is defined as any of the following:
Death (all-cause mortality)
Atrial septostomy
Hospitalization due to worsening of PAH (adjudicated)
Start of new specific PAH TX (endothelin receptor antagonists [ERAs], phosphodiesterase type-5 [PDE-5] inhibitors or prostanoids), an increase in the dose of an ERA or PDE-5, increase in the dose or frequency of an inhaled prostanoids, or an increase in the dose of an intravenous or subcutaneous prostanoids by &gt;10%.
Decrease of &gt;15% from baseline or &gt;30% compared with the last study related measurement in 6MWD should be confirmed by a repeat measurement performed at least 14 days later
Worsening of WHO Functional Class (e.g., from Class II to Class III or IV, OR Class III to Class IV); and confirmed by a repeat assessment at least 14 days later</outcome>
      <timepoint>baseline to 18 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in World Health Organization (WHO) Functional Class - Change in World Health Organization (WHO) Functional Class from baseline to 18 weeks</outcome>
      <timepoint>from baseline to 18 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Signed Informed Consent Form (and assent as appropriate) prior to the initiation of
             any study mandated procedures or assessments

          2. A confirmed diagnosis of PAH Group 1 who have either idiopathic PAH (IPAH), heritable
             PAH, drug and toxin-induced PAH, associated PAH (APAH) with connective tissue disease
             (CTD), APAH with repaired simple congenital systemic to pulmonary shunt (i.e., atrial
             septal defect, ventricular septal defect and/or patent ductus arteriosus; complete
             repair at least 1 year prior to Screening), APAH with human immunodeficiency virus
             (HIV), or APAH with portal hypertension

          3. Subjects receiving at least one PAH specific therapy (ERA or PDE-5 inhibitor, or
             inhaled, subcutaneous, or intravenous prostacyclin or a prostacyclin analog) with the
             same type of therapy for at least 3 months with stable dosing 4 weeks prior to
             Screening. (Subjects should be receiving optimal therapy according to the disease
             severity)

          4. Subjects using oxygen therapy by nasal cannula for at least 4 weeks prior to Screening

          5. PAH diagnosis confirmed by RHC within the previous 5 years, according to the following
             definitions:

               -  PVR = 400 dynes.sec.cm-5 (5 Wood units)

               -  mPAP = 25 mmHg

               -  PCWP or LVEDP = 15 mmHg

               -  Subjects who otherwise meet all the inclusion criteria and none of the exclusion
                  criteria but have not undergone a RHC within the previous 5 years may be
                  considered eligible for the study if they undergo a RHC and then meet the
                  pulmonary hemodynamics criterion

          6. 6MWD = 100 meters and = 450 meters prior to randomization

          7. WHO Functional Class II-IV. Subjects with WHO Functional Class IV should be treated
             with prostacyclin or a prostacyclin analog (subcutaneous or intravenous), plus at
             least one additional PAH specific therapy (ERA or PDE-5), if available to the subject
             and reimbursed by health insurance

          8. Age between 18 and 85 years (inclusive)

          9. Willingness to use INOpulse delivery device for at least 12 hours per day

         10. Willingness to continue on study drug until the subject has completed Week 18
             assessments (EOS)

         11. Female subjects of childbearing potential must have a negative pre-treatment pregnancy
             test (serum or urine). All female subjects should take adequate precaution to avoid
             pregnancy.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Subjects with known HIV infection who have a history within the past 3 months of any
             opportunistic pulmonary disease (e.g., tuberculosis, Pneumocystis carinii pneumonia,
             or other pneumonias) at the time of Screening

          2. PAH associated with untreated thyroid disorders, glycogen storage disease, Gaucher's
             disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative
             disorders or splenectomy

          3. Subjects with pulmonary conditions that may contribute to PAH including, but not
             limited to, chronic bronchiectasis, cystic fibrosis, or other pulmonary condition that
             the Investigator may deem to contribute to the severity of the disease or impair the
             delivery of iNO due to airway disease

          4. Subjects receiving riociguat

          5. Subjects receiving oral prostanoids as monotherapy

          6. PAH associated with significant venous or capillary involvement, known or suspected
             pulmonary veno-occlusive disease, or pulmonary capillary hemangiomatosis

          7. Any subject with WHO PH Groups 2, 3, 4 or 5

          8. Subjects with any of the following cardiac abnormalities:

               1. Underlying cardiomyopathy or clinically significant aortic or mitral valve
                  disease in the opinion of the investigator

               2. Left ventricular systolic dysfunction (LVSD), i.e., left ventricular ejection
                  fraction (LVEF) &lt; 40% or left ventricular shortening fraction (LVSF) &lt; 22%, as
                  determined by local reading

               3. Current symptomatic coronary artery disease, myocardial infarction within 1 year,
                  or any coronary artery interventions within 6 months

          9. Systemic hypertension defined as systolic blood pressure (SBP) &gt; 160 mmHg and/or
             diastolic blood pressure (DBP) &gt; 100 mmHg persistent at Screening after a period of
             rest (treated or untreated)

         10. Subjects with a history of deep vein thrombosis, pulmonary embolism/infarction or
             prothrombotic disorder must have had chronic thromboembolic pulmonary hypertension
             (CTEPH) excluded by ventilation/perfusion lung (V/Q) scan

         11. Severe obstructive lung disease defined as both a forced expiratory volume in 1
             second/forced vital capacity (FEV1/FVC) &lt; 70% and FEV1 &lt; 55% of predicted value

         12. Moderate to severe restrictive lung disease: total lung capacity (TLC) &lt; 60% of
             predicted; if TLC 60% to 70% predicted, a high resolution CT scan showing diffuse
             disease or more than mild patchy disease

         13. Any subject who develops or has developed a PCWP &gt; 20 mmHg during acute vasodilator
             testing (AVT)

         14. Systemic hypotension defined as SBP &lt; 90 mmHg persistent at Screening after a period
             of rest

         15. Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C

         16. On dialysis

         17. Acute or chronic physical impairment (other than dyspnea due to PAH) that would limit
             the ability to comply with study procedures or adherence to therapy (i.e., 6MWT),
             including carrying and wearing the pulsed delivery device per study protocol, or
             medical problem(s) likely to preclude completion of the study

         18. Pregnant or breastfeeding females at Screening

         19. Administered L-arginine within 1 month prior to Screening

         20. Known concomitant life-threatening disease with a life expectancy less than 1 year

         21. Atrial septostomy within 3 months preceding randomization

         22. The concurrent use of the INOpulse device with a continuous positive airway pressure
             (CPAP), Bilevel positive airway presure BiPAP, or any other positive pressure device.

         23. Use of investigational drugs or devices within 1 month prior to Screening (other than
             acute vasodilator testing with iNO)

         24. Any underlying medical or psychiatric condition that, in the opinion of the
             Investigator, makes the subject an unsuitable candidate for the study

         25. Any subject who has been enrolled in any previous clinical study with inhaled NO
             administered through pulse delivery.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>188</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,TAS,VIC</recruitmentstate>
    <hospital>St Vincent's Public Hospital - Darlinghurst</hospital>
    <hospital>Nepean Hospital - Kingswood</hospital>
    <hospital>Macquarie University Hospital - Sydney</hospital>
    <hospital>Concord Repatriation General Hospital - Sydney</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Australian Respiratory and Sleep Medicine Institute (ARASMI) - Bedford Park</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2747 - Kingswood</postcode>
    <postcode>2109 - Sydney</postcode>
    <postcode>2139 - Sydney</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>7000 - Hobart</postcode>
    <postcode>3004 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Tirol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brabant</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Bohemia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Comte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Normandy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rhone</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-Württemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bayern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mecklenburg-Vorpommern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Niedersachsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Sachsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Thüringen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ashqelon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Beer Sheba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Holon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Kfar Saba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Peta? Tiqwa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>BG</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>MI</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>RM</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisbon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Mondego</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Belgrade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Nis</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>A Coruña</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Canarias</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cantabria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Castile - La Mancha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Mallorca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valladolid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Dnepropetrovsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kharkiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kyiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Lviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newcastle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>West Dunbartonshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bellerophon Pulse Technologies</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Worldwide Clinical Trials</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Phase 3, placebo controlled, double-blind, randomized clinical study to determine safety,
      tolerability, and efficacy of pulsed, inhaled nitric oxide (iNO) versus placebo in
      symptomatic subjects with pulmonary arterial hypertension (PAH). Part 1 and Part 2</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02725372</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Deborah Quinn, MD</name>
      <address>Bellerophon Therapuetics</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Deena Peace</name>
      <address />
      <phone />
      <fax />
      <email>deena.peace@bellerophon.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>